WallStreetZenWallStreetZen

NYSEMKT: CANF
Can Fite Biopharma Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Can Fite Biopharma revenue was $560.00k for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CANF annual revenue was $674.0k, with -9.3% growth year-over-year.

CANF past revenue growth

How has CANF's revenue growth performed historically?

Company
-16.04%
Industry
288.26%
Market
22.68%
CANF's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CANF's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CANF's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CANF revenue history

Current Revenue
$560.0k
Current Earnings
-$8.8M
Current Profit Margin
-1,571.3%

Be the first to know when CANF announces revenue.

CANF Revenue History By Year

CANF Yearly RevenueCANF RevenueCANF ChangeCANF Revenue Growth
2024-12-31$674.00k-$69.00k-9.29%
2023-12-31$743.00k-$67.00k-8.27%
2022-12-31$810.00k-$43.00k-5.04%
2021-12-31$853.00k$90.00k+11.80%
2020-12-31$763.00k-$1.27M-62.45%
2019-12-31$2.03M-$1.79M-46.81%
2018-12-31$3.82M$3.03M+384.16%
2017-12-31$789.00k$624.00k+378.18%
2016-12-31$165.00k$3.00k+1.85%
2015-12-31$162.00kN/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A
2012-12-31$0.00-$481.95k-100.00%
2011-12-31$481.95k-$231.93k-32.49%
2010-12-31$713.88kN/AN/A

1 of 1

Can Fite Biopharma Revenue FAQ

What was CANF's revenue last quarter?

Can Fite Biopharma (NYSEMKT: CANF) reported Q2 2025 revenue of N/A up N/A year over year. In the same quarter last year, Can Fite Biopharma's revenue was N/A.

What was Can Fite Biopharma's revenue in 2024?

Can Fite Biopharma's annual revenue for the twelve months ending Dec 31, 2024 was $674.00 thousand, a 9.29% decrease year over year.

How much does Can Fite Biopharma make in a day?

Based on Can Fite Biopharma annual revenue for the past five years, CANF makes an average of $2,105.75 per day.

What was Can Fite Biopharma's annual revenue growth in the past year?

As of Q4 2025, Can Fite Biopharma's revenue has grown -16.04% year over year. This is 304.31 percentage points lower than the US Biotechnology industry revenue growth rate of 288.26%. Can Fite Biopharma's revenue in the past year totaled $560.00 thousand.

How much does Can Fite Biopharma make in a year?

Can Fite Biopharma's revenue by year for the past five years is:
  • Can Fite Biopharma's revenue for the twelve months ending Dec 31, 2024 was $674.00 thousand, a 9.29% decrease year over year.
  • Can Fite Biopharma's annual revenue for Dec 31, 2023 was $743.00 thousand, a 8.27% decrease from 2022.
  • Can Fite Biopharma's annual revenue for 2022 was $810.00 thousand, a 5.04% decrease from 2021.
  • Can Fite Biopharma's annual revenue for 2021 was $853.00 thousand, a 11.8% increase from 2020.
  • Can Fite Biopharma's annual revenue for 2020 was $763.00 thousand, a 62.45% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.